This study aimed to assess the effects of dugite envenoming on blood coagulation and platelet count in a canine model, and the efficacy of fresh frozen plasma (FFP) in reversing the clotting disorder after both adequate and inadequate venom neutralization. Following initial dosing and administration studies, an intravenous venom dose of 1µg/kg was administered to eleven dogs. This was followed 30 minutes later by antivenom in either adequate or inadequate doses. A further 30 minutes later, the animals were given either two units of their own FFP or saline. Fibrinogen, aPTT and platelet levels were monitored for eight hours.
Snakebite is a relatively common medical emergency in Australia, with up to 3,000 people a year bitten, and up to 500 requiring antivenom 1 . Improvements in first aid and medical management, particularly the introduction of specific antivenoms, resulted in a fall in mortality over the twentieth century. However, there remains a persistent mortality of around four deaths annually. The majority of deaths are now due to Brown Snake envenoming 2, 3 .
Brown Snakes belong to the genus Pseudonaja, which includes three species of snake that are regarded as being dangerous to humans. These are the gwardar (Pseudonaja nuchalis), the common or Eastern Brown (Pseudonaja textilis) and the dugite (Pseudonaja affinis). Brown Snake venom contains components that activate the clotting mechanism in the blood 4, 5 . The result is a depletion of clotting factors, which are consumed in the clotting process. This consumptive coagulopathy results in afibrinogenaemia and leaves the snakebite victim at serious risk of spontaneous bleeding. Although most deaths occur outside hospital, associated with sudden collapse soon after the bite, death in hospital is commonly due to cerebral haemorrhage 2, 6, 7 .
The accepted treatment of elapid snake envenoming is first aid with pressure immobilization bandaging, transfer to hospital and then intravenous administration of appropriate snake antivenom 4 . There is currently debate in the literature as to the amount of antivenom that needs to be given in order to achieve complete neutralization of Brown Snake venom, with in vitro and animal research demonstrating that 15 to 20 times the dose of antivenom initially recommended by Commonwealth Serum Laboratories needs to be administered for adequate venom neutralization 8, 9 . This is supported by clinical data showing that large doses of antivenom (10 to 20 or more units) are commonly given to victims of Brown Snake envenoming 10, 11 . Most of these data are from studies in Perth, Western Australia, where the dugite is the common Brown Snake responsible for most envenomings.
After Brown Snake antivenom has been administered, many clinicians also give blood products such as fresh frozen plasma (FFP) in an attempt to reverse the coagulopathic state, although there is no evidence of its efficacy. The rationale for transfusing FFP is that the bleeding disorder results from consumption of the clotting factors, therefore replacing the clotting factors with the FFP may reduce the risk of spontaneous bleeding. However, the addition of clotting factors may accelerate their consumption and actually increase the risk of bleeding, especially if there is inadequate venom neutralization. Additionally, products of clotting factor consumption may induce coagulopathy.
There are currently no data to determine whether FFP should be given to patients with coagulopathy after snake envenoming.
The study aimed to assess in a canine model of envenoming the effect of dugite venom on blood coagulation and platelet count, and the efficacy of FFP in reversing the clotting disorder after both adequate and inadequate venom neutralization. The study incorporates the situations of adequately and inadequately neutralized venom, both of which can occur in clinical practice.
METHODS

General care, FFP collection, ethics, and anaesthesia of animals
Mongrel dogs of weight approximately 13 to 25 kg awaiting euthanasia were obtained from the Perth City Pound. The dogs were kept for seven days in the Animal Research Laboratory, University of Western Australia, before being entered into the study. They were fed, housed and cared for by qualified animal technicians. All envenoming, dosing and treatment procedures occurred whilst the animals were fully anaesthetized. After the experiment was completed the animals were euthanased with pentobarbitone.
All procedures carried out on dogs were in accordance with the NHMRC Australian Code of Practice for the Care and Use of Animals for Scientific Purposes and approved by the Animal Ethics Committee of the University of Western Australia.
Animals enrolled in the FFP treatment arm of the study were venesected at one and four days after arrival at the animal facility. On each occasion 10 ml/kg of whole blood was removed. The blood was then centrifuged by the Senior Coagulation Scientist (NM), PathCentre, Queen Elizabeth II Medical Centre, and used to derive FFP. Two units (10 ml/kg) of the animal's own FFP was then available for transfusion in the treatment arm of the experiment. Three days were allowed after each venesection to allow ample time for recovery prior to the study beginning on day 7.
Blood samples were taken prior to induction of anaesthesia to assess baseline haemoglobin levels and packed cell volume (PCV). Murdoch University Veterinary School Haematological Reference Ranges for dogs were used for normal values and to compare animals' baseline levels. For haemoglobin this was 120-180 g/l, and PCV 0.37-0.55. Animals with baseline values outside the normal range were not to be used, however all dogs fell within these parameters. Platelet count normal values were 200-900×10 9 /l, and activated partial thromboplastin time (aPTT) 13.5 to 19.3 seconds.
The dogs were premedicated with a subcutaneous injection of acepromazine (ANAMAV™, Mavlabs, Slacks Creek, QLD) at a dose of 0.5 to 1.0 ml/10 kg. The dogs were anaesthetized with a mixture of halothane and oxygen, followed by endotracheal intubation. They were anaesthetized to a degree that allowed spontaneous respiration. Anaesthesia was maintained with halothane, oxygen and air for eight hours to allow enough time for the regeneration of clotting factors. The dogs underwent a series of monitoring procedures during the period of anaesthesia, including continuous ECG, pulse oximetry and rectal temperature, and blood pressure measurements every 15 minutes during the first hour of anaesthesia, then every 30 minutes thereafter.
Anaesthesia and Intensive Care, Vol. 33, No. 1, February 2005 Antivenom/fresh frozen plasma treatment studies Dugite venom was purchased from Venom Supplies, Tanunda, South Australia. After testing dose and route of administration in mongrel dogs, an intravenous injection protocol at a dose of 1 µg/kg, diluted in saline 100 ml and administered intravenously over five minutes, was adopted for the study.
Thirty minutes following the intravenous administration of 1 µg/kg of dugite venom, Brown Snake antivenom (Commonwealth Serum Laboratories, Melbourne, Vic.) was given intravenously. The Commonwealth Serum Laboratories (CSL) recommended dose of antivenom for dugite envenoming at the time was 1 unit per 10 µg venom. However, on the basis of considerable in vitro, animal and now clinical data [8] [9] [10] [11] , the CSL-recommended dose has been shown to be inadequate to neutralize Brown Snake venom. In this study a minimum of 20 times this amount (1 unit of antivenom per 0.5 µg of venom) was considered adequate to neutralize administered venom. To reflect clinical practice in humans, dogs were given a range of doses of antivenom, either categorized as adequate if at this dose (1U/0.5 µg venom) or higher, or inadequate, at a concentration of 200 U/ml diluted to 50 ml with normal saline and infused over 15 minutes. After waiting a further 15 minutes, two units of the animal's own FFP (derived as described above) or an equal volume of saline was infused over 15 minutes.
Thus there were four treatment groups; those treated with an inadequate dose of antivenom and no FFP; those treated with an inadequate dose of antivenom plus two units of FFP; those treated with an adequate dose of antivenom and no FFP; and those treated with an adequate dose of antivenom and two units of FFP. All four states were investigated as it was considered feasible that all may occur in clinical practice.
Investigations
In all four groups blood samples were collected at the following time points; 0 minutes (immediately prior to envenoming), 15 minutes, 30 minutes (immediately prior to antivenom infusion), 45 minutes, 60 minutes (immediately prior to FFP/saline infusion), 75, 90, 120, 240, and 480 minutes. The samples were transported immediately to the Haematology Department, Pathcentre, Queen Elizabeth II Medical Centre. Standard laboratory techniques were used to measure aPTT, fibrinogen level, and full blood count including platelet count.
RESULTS
Initial dosing and route of administration studies showed that intravenous venom administration in an initial dose of 10 µg/kg resulted in immediate death of both tested animals. Post mortem examination of these dogs showed large clots throughout the heart chambers. Surprisingly, a coagulopathy could not be induced with subcutaneous administration of 10, 50, 100 or 150 µg/kg of venom. The lower dose of 1 µg/kg of venom intravenously ensured survival of most dogs, although one still died before antivenom could be administered. All developed typical afibrinogenaemia and elevated aPTT consistent with the defibrination syndrome seen in Brown Snake envenoming.
Eleven dogs were then treated in all (Table 1) . Five dogs were treated with no FFP, two with an inadequate dose of antivenom and three with an adequate dose. Six dogs were treated with FFP, two with an inadequate dose of antivenom, and four with an adequate dose. Records of the weight of one dog were lost, although antivenom dose/µg of venom was recorded.
Baseline fibrinogen levels varied from 1.2 to 3.8 g/l, except for one dog with a level of 7.4. All dogs developed a coagulopathy, with the time to minimum detectable fibrinogen varying from 15 to 75 minutes after venom administration. All had elevated aPTTs, all of which improved with treatment, except in those dogs that died.
Of the five dogs treated with antivenom only, and no FFP, all but one had return of detectable fibrinogen at eight hours after envenoming. This dog had received an adequate dose of antivenom. Both dogs receiving an inadequate dose of antivenom had return of measurable fibrinogen by eight hours.
Of the six dogs treated with antivenom plus FFP, two died and all but one of the survivors had persistent afibrinogenaemia at eight hours post envenoming. The only dog to develop a measurable level of fibrinogen by eight hours post envenoming had received an inadequate dose of antivenom. Of the two dogs dying after FFP treatment, one had inadequate antivenom and the other adequate antivenom. Both animals arrested after developing bradycardia and died between 60 and 90 minutes post envenoming, at the end of the FFP infusions. Both failed to defibrinate prior to death.
The platelet count fell in all animals, in some quite dramatically ( Table 1 ). The largest fall was from 264 to 41×10 9 /l. The platelet counts fell to their lowest points by 45 to 75 minutes post envenoming, and then increased but only in one animal back to their baseline level. Whether the dose of antivenom was adequate or FFP was given or not did not appear to influence these changes.
DISCUSSION
While FFP is commonly given to patients with afibrinogenaemia after snake envenoming, there has been no experimental work to confirm its value. It has been stated that adequate venom neutralization with antivenom is sufficient therapy, allowing clotting factors to regenerate spontaneously 1 . There is the possibility that the common practice of administration of FFP or other clotting factors may actually worsen the outcome, particularly if venom is inadequately neutralized, and administered clotting factors are simply consumed in the clotting process.
We found, in this canine model of Brown Snake envenoming, that FFP administration seemed to adversely affect the coagulopathy. FFP, except in one animal, was associated with persistent afibrinogenaemia for the eight hour period studied. Except for one dog, all dogs which did not receive FFP had detectable fibrinogen by eight hours. The adequacy of venom neutralization was not an important determinant of whether the afibrinogenaemia resolved. Additionally, the only deaths in this treatment study after administration of antivenom were two dogs in the FFP treated group. Of note, neither of these two dogs defibrinated before death, raising the possibility that a mechanism unrelated to the procoagulant in the venom was involved.
A number of other important observations were made in this study. It has been known for some time that Brown Snake envenoming causes rapid collapse and death in a number of patients. The mechanism is unclear. It has been postulated that this may be due to transient myocardial dysfunction and hypotension due to intravascular clotting 4, 12, 13 . In the initial dosing study, we found that when using an intravenous dose of 10 µg/kg of venom, we were unable to induce a coagulopathy in dogs without causing death from massive intravascular clotting. The two dogs on which we performed post mortems both demonstrated large intracardiac clots. This lends weight to the view that intravascular clotting, perhaps particularly in the heart, may cause this collapse in humans. The issue of whether Brown Snake venoms induce thrombocytopenia has been controversial. Marshall and Herrmann showed that the venom of all tested Australian elapid snakes caused platelets to irreversibly aggregate in vitro 14 . Thrombocytopenia has previously been documented in a canine model of envenoming 12, 15 . Morling and co-workers noted that nearly half of their studied patients developed thrombocytopenia after Brown Snake envenoming, but not after Tiger Snake envenoming 16 . We found that the platelet count routinely fell in all tested dogs, presumably due to the direct effect noted by Marshall and Herrmann and in association with widespread intravascular clotting. The platelet count recovered in all dogs that survived, but not completely within the eight hours of blood testing, whether antivenom treatment had been adequate or not, even when fibrinogen had not yet been regenerated.
This study used small subject numbers of an animal model, hence generalizability to human envenoming is limited. It is possible the experimental design made the FFP treated animals more susceptible to the effects of dugite venom in that they were venesected 20ml/kg of blood prior to the experiment. However, ample time was allowed for recovery prior to envenoming, the dogs' haematocrits were within the normal range, and in those dogs who survived, the coagulopathy did not resolve as well as in those dogs not treated with FFP.
CONCLUSION
In this canine model of Brown Snake envenoming, we found that FFP administration had adverse affects. While controlled human studies would better resolve the question of whether to use FFP as an adjunct to definitive antivenom treatment for the coagulopathy of snake envenoming in humans, this study raises serious questions about its current common use. In the absence of any evidence for its efficacy, it may be prudent not to give such patients FFP until there is clear evidence of benefit.
